UNICREDIT BANK/CALL/MODERNA/130/0.1/18.09.24 | Market Closed - Borsa Italiana 16:04:59 2024-05-17 EDT | ||
| 1.625 EUR | -1.52% |
|
| Current month | +94.35% | ||
| 1 month | +146.27% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 1.65 | 0.00% |
| 24-05-16 | 1.65 | +11.26% |
| 24-05-15 | 1.483 | -0.80% |
| 24-05-14 | 1.495 | +11.99% |
| 24-05-13 | 1.335 | +44.17% |
Real-time Borsa Italiana
Last update May 17, 2024 at 04:04 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
UniCredit
|
| UD1F90 | |
| ISIN | DE000HD1F907 |
| Date issued | 2023-12-27 |
| Strike | 130 $ |
| Maturity | 2024-09-18 (122 Days) |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.8 € |
|---|---|
| Lowest since issue | 0.384 € |
| Spread | 0.01 € |
| Spread % | 0.61% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
132.9
USD
Average target price
138.5
USD
Spread / Average Target
+4.22%
- Stock Market
- Warrants
- UD1F90 Warrant
